Version 2.70

97097-0SARS-CoV-2 (COVID-19) Ag [Presence] in Upper respiratory specimen by Rapid immunoassayActive

Term Description

Qualitative detection of SARS coronavirus 2 (SARS-CoV-2) antigen in upper respiratory specimens, such as nasopharyngeal swabs, by rapid immunoassay methods. Testing is performed for the diagnosis of Coronavirus Disease 2019 (COVID-19).
Source: Regenstrief LOINC

Part Description

LP417540-4   SARS coronavirus 2
The 2019 Novel Coronavirus (2019-nCoV) is a coronavirus first identified as the cause of a respiratory illness outbreak in Wuhan, China. Initially, the outbreak was linked to a large seafood and animal market and thought to only be spread by animal to person contact. Within a short time, a growing number of patients who had not been exposed to animal markets were diagnosed with the infection, indicating person-to-person transmission. As of January 2020, infections with 2019-nCoV have been reported internationally, including Thailand and the United States, in due to confirmed cases in travelers from Wuhan. Overall, clinical symptoms appear milder than SARS Coronavirus (SARS-CoV) and Middle East Respiratory Syndrome (MERS) Coronavirus (MERS-CoV) infections as do the fatality rate and transmissibility. [PMID: 31953166] Reported illnesses have ranged from minor or no respiratory symptoms to severe acute respiratory illness and death.

The full genome of the 2019-nCoV was first posted by Chinese health authorities in GenBank, the NIH genetic sequence database, and in the Global Initiative on Sharing All Influenza Data (GISAI) portal. This facilitated detection of the virus globally with subsequent sequences being nearly identical, suggesting a single, recent emergence from a virus related to bat coronaviruses and the SARS coronavirus. Real time Reverse Transcription-Polymerase Chain Reaction (rRT-PCR) tests have been developed by the Centers for Disease Control and Prevention (CDC) and others for the diagnosis of 2019-nCoV. The existing 2019-nCoV primer and probe sets are designed for the universal detection of SARS-like coronaviruses and for specific detection of 2019-nCoV.[CDC: coronavirus/2019-ncov] Source: LOINC

Fully-Specified Name

SARS coronavirus 2 Ag

Additional Names

Short Name
SARS-CoV-2 Ag Upper resp Ql IA.rapid
Display Name
SARS-CoV-2 (COVID-19) Ag IA.rapid Ql (Upper resp)
Consumer Name Alpha
SARS-CoV-2 (COVID-19) antigen, Upper respiratory

Example Answer List LL744-4

Source: Regenstrief Institute

Answer Code Score Answer ID
Detected LA11882-0
Not detected LA11883-8

Basic Attributes

First Released
Version 2.70
Last Updated
Version 2.70
Order vs. Observation

Member of these Panels

LOINC Long Common Name
97099-6 Influenza virus A and B and SARS-CoV-2 (COVID-19) Ag panel - Upper respiratory specimen by Rapid immunoassay

Member of these Groups

LG51046-7 SARS coronavirus 2 Ag|PrThr|Sys:ANYResp
LG51017-8 SARSCoV2 detection

Language Variants Get Info

zh-CNChinese (China)
SARS 冠状病毒 2 抗原:存在情况或阈值:时间点:呼吸道.上:序数型:免疫测定法.快速
nl-NLDutch (Netherlands)
SARS-CoV-2 Ag:aanwezigheid:moment:bovenste luchtwegen:ordinaal:immunoassay.sneltest
it-ITItalian (Italy)
SARS coronavirus 2 , Ag:PrThr:Pt:Sistema respiratorio.superiore:Ord:IA.rapido
es-ESSpanish (Spain)
Panel del SARS-CoV-2 (COVID-19) Antígeno:PrThr:Punto temporal:Muestra respiratoria de vías altas:Ord:IA.rapid

LOINC FHIR® API Example - CodeSystem Request Get Info